This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document.
The compatibility of combinations of doxorubicin, cyclophosphamide, cisplatin and etoposide used in the DT-PACE protocol for multiple myeloma:
- Cisplatin and etoposide can be combined together in 1000 mL sodium chloride 0.9%.r
- Doxorubicin and cyclophosphamide can be combined together in 1000 mL sodium chloride 0.9% with expiry of 7 days (at room temperature or refrigerated).r
Alternatively:
- Cyclophosphamide and etoposide can be combined together in one bag with expiry of 7 days at room temperature.r
While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au
Send feedback for this page
- Last reviewed:
-
- Review due:
-
The currency of this information is guaranteed only up until the date of printing, for any updates please check:
https://www.eviq.org.au/p/3048
21 Apr 2024